Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Med (New York, N.Y.)
|
December 9, 2020
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
Philip C Robinson, David F L Liew, Jean W Liew, et al.
British Journal of Clinical Pharmacology
|
October 30, 2023
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2
Helen E Higham, Lauren Morgan, Cushla Cooper, et al.
Trials
|
August 19, 2020
A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial
Timothy S C Hinks, Vicki S Barber, Joanna Black, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 6, 2022
COVID-19 therapeutics: Challenges and directions for the future
Philip C Robinson, David F L Liew, Helen L Tanner, et al.
JPEN. Journal of Parenteral and Enteral Nutrition
|
June 30, 2018
Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study
Adam M Deane, Francois Lamontagne, George E Dukes, et al.
BMC Gastroenterology
|
July 20, 2016
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial
Vinod S Hegade, Stuart F W Kendrick, Robert L Dobbins, et al.
BMJ Open
|
November 12, 2021
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Tonny Veenith, Benjamin A Fisher, Daniel Slade, et al.
Lancet (London, England)
|
February 12, 2017
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study
Vinod S Hegade, Stuart F W Kendrick, Robert L Dobbins, et al.
BMJ Open
|
September 28, 2023
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis
Alexander Ooms, Hussein Al-Mossawi, Louise Bennett, et al.
BMJ Open
|
July 10, 2026
Clinical and cost-effectiveness of oral versus intramuscular glucocorticoids in rheumatoid arthritis: protocol for a multicentre randomised controlled trial with economic evaluation and qualitative sub-study (LEADER trial)
Jonathan Alistair Cook, Nicky Wilson, Kate Wilkins, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Med (New York, N.Y.)
|
December 9, 2020
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
Philip C Robinson, David F L Liew, Jean W Liew, et al.
British Journal of Clinical Pharmacology
|
October 30, 2023
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2
Helen E Higham, Lauren Morgan, Cushla Cooper, et al.
Trials
|
August 19, 2020
A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial
Timothy S C Hinks, Vicki S Barber, Joanna Black, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 6, 2022
COVID-19 therapeutics: Challenges and directions for the future
Philip C Robinson, David F L Liew, Helen L Tanner, et al.
JPEN. Journal of Parenteral and Enteral Nutrition
|
June 30, 2018
Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study
Adam M Deane, Francois Lamontagne, George E Dukes, et al.
BMC Gastroenterology
|
July 20, 2016
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial
Vinod S Hegade, Stuart F W Kendrick, Robert L Dobbins, et al.
BMJ Open
|
November 12, 2021
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Tonny Veenith, Benjamin A Fisher, Daniel Slade, et al.
Lancet (London, England)
|
February 12, 2017
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study
Vinod S Hegade, Stuart F W Kendrick, Robert L Dobbins, et al.
BMJ Open
|
September 28, 2023
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis
Alexander Ooms, Hussein Al-Mossawi, Louise Bennett, et al.
BMJ Open
|
July 10, 2026
Clinical and cost-effectiveness of oral versus intramuscular glucocorticoids in rheumatoid arthritis: protocol for a multicentre randomised controlled trial with economic evaluation and qualitative sub-study (LEADER trial)
Jonathan Alistair Cook, Nicky Wilson, Kate Wilkins, et al.
Page
of 4